Mantle Cell Lymphoma

The FDA granted accelerated approval to pirtobrutinib for treatment of certain patients with advanced mantle cell lymphoma.

NEW ORLEANS — Patients with newly diagnosed mantle cell lymphoma who received ibrutinib with a standard-of-care regimen had higher failure-free survival rates than those who received standard-of-care treatment alone.

Oncologists who treat non-Hodgkin lymphoma have increasingly become reliant on targeted treatment, with several new agents receiving FDA approval within the past 5 years.

CHICAGO — A novel first-line regimen significantly improved PFS compared with standard chemoimmunotherapy for older patients with mantle cell lymphoma, according to randomized phase 3 study results presented at ASCO Annual Meeting.

As new therapeutic options for mantle cell lymphoma emerge, physicians are learning where they best fit into the treatment armamentarium.

The FDA granted priority review to parsaclisib for two lymphoma indications.

The FDA granted breakthrough therapy designation to orelabrutinib for the treatment of patients with relapsed or refractory mantle cell lymphoma, according to a manufacturer-issued press release.

Patients with mantle cell lymphoma who were unmarried, had less education or had more comorbidities appeared less likely to undergo autologous hematopoietic stem cell transplantation, according to a study published in Blood Advances.

LOXO-305, a novel non-covalent BTK inhibitor, was active in B-cell malignancies, including chronic lymphocytic leukemia and mantle cell lymphoma, according to data presented at the ASH Annual Meeting and Exposition.

Ibrutinib — a Bruton tyrosine kinase inhibitor that inhibits B cell-receptor signaling — has demonstrated long-term efficacy as treatment for many mature B-cell malignancies, including chronic lymphocytic leukemia and mantle cell lymphoma.